1204222-75-2

Upstream product

• 114-70-5 sodium phenylacetate 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 51086-45-4 2,2-dideuterio-2-phenyl-ethanol 
• 1076-07-9 2,2-dideuterio-2-phenyl-acetic acid 
• 1204222-67-2 (5-bromo-2-chlorophenyl)(4-(2,2-dibromocyclopropyl-1-d)phenyl)methanone 
• 1204222-71-8 4-bromo-1-chloro-2-(4-(cyclopropyl-1-d)benzyl)benzene 
• 1204222-65-0 (2,2-dibromocyclopropyl-1-d)benzene 
• 23088-37-1 2,2-d₂-phenethyl bromide 
• 67-56-1 methanol 
• 1204222-73-0 4-bromo-1-chloro-2-((4-(cyclopropyl-1-d)phenyl)methyl-d2)benzene 
• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 

Downstream Products

• 1204222-77-4 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(cyclopropyl-1-d)phenyl)methyl-d2)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 

Relevant academic research and scientific papers

DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.